Earnings call transcript: Ascend Wellness Q4 2025 misses forecasts, stock dips

Ascend Wellness reported Q4 2025 EPS of -$0.24 versus a -$0.10 forecast (140% negative surprise) and revenue of $120.5M versus $122.35M expected (miss of 1.51%), with revenue down 3.4% QoQ. Adjusted EBITDA was $30.2M (margin improved 20 bps to 25.1%) and ending cash was $85.7M, but the stock fell ~1.9% after hours and remains down materially YTD; company expects low- to mid-single-digit top-line decline in Q1 while pursuing retail densification, cost savings and tuck-in M&A.

Analysis

Ascend’s set of strategic moves (retail-first densification, SKU premiumization, and aggressive cost-out) shifts its revenue mix into a higher-margin, higher-variance model — good for long-term unit economics but bad for near-term top-line predictability. The practical consequence: revenue becomes more dependent on execution of approvals and retail footfall rather than broad wholesale distribution, concentrating regulatory and timing risk into fewer, larger binary events over the next 6–18 months.

Price compression in competitive Northeastern and Midwestern markets is not just a margin issue — it is a liquidity and working-capital stress test for producers and distributors that maintain large wholesale channels. Expect this to accelerate consolidation among smaller wholesalers and force national players to choose between margin-dilutive share gains or disciplined pricing that slows growth; that bifurcation creates asymmetric outcomes for equity vs. credit holders across the sector.

Macro/regulatory catalysts (rescheduling, a potential hemp-intoxicant ban) remain the dominant optionality embedded in the name: these are multi-quarter to multi-year binary outcomes that could re-route demand materially into the regulated channel. Until those catalysts resolve, the cleanest way to harvest upside is through structured or hedged instruments that buy the optionality of a regulatory-driven rerating while limiting exposure to execution and cadence risk in store openings and local pricing dynamics.

Key Decisions for Investors

• Tactical long-call-spread on AAWH (12-month): Buy a moderately OTM 12-month call spread to capture upside if regulatory catalysts (rescheduling/hemp restrictions) or successful densification drive a rerating. Position size 1–3% of portfolio; max loss = premium; target 2x–3x return if catalyst occurs within 6–18 months.
• Hedged equity position (collar) on AAWH: For investors willing to own stock but protect downside, buy shares and fund protective 3–6 month puts by selling 9–12 month calls (collar). This limits near-term downside from execution risks while retaining upside to multi-quarter regulatory tailwinds. Use collar strike spacing to cap downside to roughly half the notional exposure.
• Pair trade (relative-value): Long AAWH / short a larger wholesale-centric MSO (e.g., Cresco Labs CRLBF or Green Thumb GTBIF) for 6–12 months — size small (1–2% net exposure). Rationale: if vertical retail and loyalty initiatives outperform, retail-focused operators re-rate vs. wholesale-volume businesses under pressure from price compression. Risk: sector-wide sell-off will hurt both legs.
• Credit-sensitive income play: If senior secured paper for AAWH is available at elevated spreads, buy into the secured notes for income and hedge tail risk by purchasing short-dated equity puts. Time horizon 1–3 years; reward = above-market coupon with limited upside, risk = restructuring which is mitigated by purchased equity downside protection.